Stockscreener 앱 받기
3.13
0.00%
0.00
시간 외 거래:
3.18
0.05
+1.60%
전일 마감가:
$3.13
열려 있는:
$3.13
하루 거래량:
1.07M
Relative Volume:
1.28
시가총액:
$599.48M
수익:
$12.99M
순이익/손실:
$-74.39M
주가수익비율:
-7.1136
EPS:
-0.44
순현금흐름:
$-78.92M
1주 성능:
-6.29%
1개월 성능:
-12.57%
6개월 성능:
-2.80%
1년 성능:
-19.33%
1일 변동 폭
$3.10
$3.16
1주일 범위
$3.10
$3.335
52주 변동 폭
$2.705
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
명칭
Arbutus Biopharma Corp
전화
604-419-3200
주소
701 VETERANS CIRCLE, WARMINSTER, PA
ABUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.13 | 639.70M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-02-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 개시 | Jefferies | Hold |
| 2020-12-17 | 개시 | H.C. Wainwright | Buy |
| 2020-07-27 | 재개 | JMP Securities | Mkt Outperform |
| 2020-07-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-06 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 개시 | Robert W. Baird | Outperform |
| 2020-02-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 재확인 | B. Riley FBR | Buy |
| 2019-10-04 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2018-10-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-06 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 재개 | Chardan Capital Markets | Buy |
| 2018-03-19 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 재확인 | Wedbush | Outperform |
| 2016-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
모두보기
Arbutus Biopharma Corp 주식(ABUS)의 최신 뉴스
Why Arbutus Biopharma Corporation stock attracts strong analyst attentionBreakout Confirmation Tool - Newser
What makes Arbutus Biopharma Corporation stock price move sharplyReal Time Stock Signal - Newser
How Arbutus Biopharma Corporation stock performs during market volatilityFree Daily Stock Market Updates - Newser
Arbutus Biopharma (ABUS) Reacquires China Rights to Lead Drug | - GuruFocus
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus - Yahoo Finance
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Ameriprise Financial Inc. Makes New $62,000 Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Bank of America Corp DE Acquires 171,906 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Millennium Management LLC Purchases 92,068 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Deutsche Bank AG Buys 75,212 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Northern Trust Corp Has $4.35 Million Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress - MyChesCo
Mercer Global Advisors Inc. ADV Makes New Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co. (NASDAQ:ABUS) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World
Arbutus: Q1 Earnings Snapshot - CT Insider
Arbutus Biopharma Corp Reports Q1 2025 Earnings: Revenue at $1.8 Million, EPS Misses Estimate with $0.13 Loss - GuruFocus
Arbutus Biopharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada
Arbutus Biopharma (ABUS) Reports Mixed Q1 Results - GuruFocus
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Arbutus (ABUS) Reports Lower Q1 Revenue Amid Promising Treatment Progress | ABUS Stock News - GuruFocus
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 - MyChesCo
Wells Fargo & Company MN Acquires 21,768 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma (ABUS) Showcases Promising Data on Imdusiran and AB-101 | ABUS Stock News - GuruFocus
Arbutus Presents Clinical Trial Data from its Two HBV - GlobeNewswire
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Barclays PLC - Defense World
Invesco Ltd. Grows Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp (ABUS) is a good investment, but the stock may be overvalued - uspostnews.com
Arbutus Biopharma Corp (ABUS) With A Potential Upside Of More Than -139.44% - Stocksregister
Arbutus Biopharma Corp (ABUS) looking to reclaim success with recent performance - Sete News
Legal & General Group Plc Has $388,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp [ABUS] Insider Activity: An Update for Investors - knoxdaily.com
Arbutus Biopharma Corp expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Stock Market Recap: Arbutus Biopharma Corp (ABUS) Concludes at 3.12, a -1.58 Surge/Decline - DWinneX
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress - MyChesCo
Arbutus Biopharma Corp (ABUS)’s stock price in review: A technical analysis - uspostnews.com
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - GlobeNewswire
Alliancebernstein L.P. Has $393,000 Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Franklin Resources Inc. Takes $301,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Vanguard Group Inc. - Defense World
Raymond James Financial Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Wellington Management Group LLP Buys 16,484 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Corebridge Financial Inc. Has $238,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
KLP Kapitalforvaltning AS Invests $84,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Teacher Retirement System of Texas Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp (ABUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.40%
2.49%
자본화:
|
볼륨(24시간):